Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib maintenance in primary platinum-resistant recurrent ovarian cancer
ChiCTR2000037709Phase 2Recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in ovarian cancer, sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoint: PFS6. Started Oct 2020; status: recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000037709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037709.